SCHEMBL4721732

SCHEMBL4721732

CCCCN(CC)c1cccc2c1[CH]c1ccccc1-2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 6/20 0.39
LMNA P02545 2/20 0.36
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
CASP1 P29466 1/20 0.32
RECQL P46063 1/20 0.32
CASP7 P55210 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31
POLB P06746 1/20 0.31
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724339 0.94 CRHR1 (0.36) CRHR1LMNAMEN1KMT2AALDH1A1
SCHEMBL4724521 0.91 CRHR1 (0.40) CRHR1LMNAMEN1KMT2AALDH1A1
SCHEMBL4723530 0.91 CRHR1 (0.35) CRHR1LMNAMEN1KMT2AKDM4E
SCHEMBL4722979 0.88 MEN1 (0.36) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL4765912 0.84 CRHR1 (0.40) CRHR1LMNAMEN1KMT2ATSHR
SCHEMBL4723422 0.84 KDM4E (0.40) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL4721790 0.77 DRD3 (0.35) CRHR1LMNAMEN1KMT2AALDH1A1
SCHEMBL4719924 0.76 TP53 (0.33) LMNAMEN1KMT2AALDH1A1TDP1
SCHEMBL25453791 0.73 CYP1A2 (0.42) CRHR1LMNAMEN1KMT2AALDH1A1
SCHEMBL215956 0.72 MAPT (0.43) LMNAMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CRHR1 3095/4885LMNA 2692/4885MEN1 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.